Evidence map›Paper›PMID 39187357›Full record

ArticleIn vivo (Athens, Greece)

The Promising Effects of Lattice Radiotherapy for Large, Fungating, or Ulcerating Breast Cancers: A Prospective Single-center Study.

Gianluca Ferini, Valentina Zagardo, Anna Viola, Domenico Patanè, Silvana Parisi, Francesco Cuccia, Antonio Piras, Paolo Fontana, Giovanni Maugeri, Angela Prestifilippo and 4 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Preoperative accelerated hypofractionated radiotherapy (PHYPORT): state of art and potential clinical application.Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology · 2025
    Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Gianluca FeriniREM Radioterapia srl, Viagrande, Italy; gianluca.ferini@grupposamed.com.
Valentina ZagardoREM Radioterapia srl, Viagrande, Italy.
Anna ViolaREM Radioterapia srl, Viagrande, Italy.
Domenico PatanèDepartment of Nursing Service, Garibaldi Hospital, Catania, Italy.
Silvana ParisiRadiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Francesco CucciaRadiation Oncology, ARNAS Civico Hospital, Palermo, Italy.
Antonio PirasRadioterapia Oncologica, Villa Santa Teresa, Palermo, Italy.
Paolo FontanaBreast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy.
Giovanni MaugeriBreast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy.
Angela PrestifilippoBreast Unit, The Mediterranean Institute of Oncology, Viagrande, Italy.
Andrea BoncoraglioRadiology Unit, Giovanni Paolo II Hospital, Ragusa, Italy.
Antonio PontorieroRadiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.
Mandara HarikarClinical Trials Programme, The University of Edinburgh, Edinburgh, U.K.
Stefano PergolizziRadiation Oncology Unit, Department of Biomedical, Dental and Morphological and Functional Imaging Sciences, University of Messina, Messina, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND/

aimTo evaluate the safety and efficacy of lattice radiotherapy (LRT) for large, inoperable breast cancers. PATIENTS AND

methodsIn this prospective study, patients who underwent LRT for breast tumors that were ulcerating/fungating/extensively eroding the chest wall, and were ineligible/unwilling for surgery, were enrolled from May 2021 to Nov 2023. Baseline Eastern Cooperative Oncology Group (ECOG) status, pre- and post-LRT numerical rating scale (NRS), and post-LRT changes in quality of life (QoL) were recorded. Survival outcomes were reported at 6 months and 1-year. Median rates of survival and dosimetric parameters were calculated. Kaplan-Meier curves for overall survival (OS), cancer-specific survival (CSS), and failure of local control (LC) were constructed.

resultsTen patients (8 females) underwent LRT. The median age was 76 years (range=57-99 years) and the median ECOG performance status was 2.5 (range=1-4). The planned schedule was completed by 9/10 patients, accounting for a 90% compliance rate. Among patients with pain (n=7), NRS rapidly reduced from 7 (range=5-10) to 3 (range=1-6). The median equivalent uniform dose was 0.71 Gy (0.09-1.59 Gy). The actuarial rates of 6-month LC, CSS, and OS were 75%, 89%, and 61%, respectively, with only LC rate changing to 50% at 1 year. Two patients had local relapse at the six-month and 1-year follow-up, respectively, after having achieved a complete response at three months, and two others died of COVID-19 infection and ischemic stroke.

conclusionLRT was found to be effective and safe in palliating symptoms among patients with large inoperable breast tumors.

Indexed as

Breast NeoplasmsQuality of LifeAgedAged, 80 and overFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm StagingProspective StudiesRadiotherapy DosageTreatment Outcomebreast cancerfungating breast cancerLattice radiotherapypalliative therapyradiation oncologyulcerating tumor

Identifiers

PMID39187357
PMCPMC11363780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.